Skip to Content

Anacor Announces Positive Results from Phase 1 Safety Trial of AN2898 for Psoriasis and Atopic Dermatitis

PALO ALTO, Calif.--(BUSINESS WIRE)--Mar 6, 2009 - <!-- cpurl -->Anacor Pharmaceuticals<!-- /cpurl --> today announced positive results from a Phase 1 clinical trial of <!-- ppurl -->AN2898<!-- /ppurl -->, an investigational topical anti-inflammatory product candidate for the potential treatment of psoriasis and atopic dermatitis. In the trial, AN2898 ointment was very well tolerated and demonstrated no irritant potential.

In this cumulative irritation trial, AN2898 ointment at 5% and its vehicle were applied daily to the skin of normal volunteers under occlusive, adhesive patches for four consecutive days. Application sites were evaluated daily for signs of irritation. No irritant potential was seen for AN2898 5% ointment or the vehicle.

“The completion of this study marks an important milestone for AN2898, our second boron-containing compound to enter clinical development for psoriasis and atopic dermatitis. We are encouraged by preliminary research demonstrating AN2898's broad cytokine profile and activity in preclinical models,” said Karl R. Beutner, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Anacor Pharmaceuticals. “We have already initiated a Phase 1b microplaque trial for AN2898 to test its ability to treat patients with psoriasis.”

AN2898 is a novel boron-containing small molecule phosphodiesterase 4 (PDE4) inhibitor that reduces the production of TNF-alpha, IL-12, IL-23, and other cytokines. Because AN2898 is applied topically, the potential for systemic side effects is anticipated to be relatively low compared to the systemically administered therapeutics.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with <!-- cpurl -->GlaxoSmithKline<!-- /cpurl -->. Anacor's most advanced product candidate is <!-- ppurl -->AN2690<!-- /ppurl -->, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to <!-- cpurl -->Schering-Plough<!-- /cpurl --> Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the progress and timing of our clinical trials and the safety and efficacy of our product candidates. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward-looking statements include, but are not limited to, undesirable effects, lack of efficacy or other developments resulting in clinical failure at later stages of development of our product candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Contact: Anacor Pharmaceuticals
Anne Bowdidge, 650-543-7575
Investor Relations

Posted: March 2009